Monday, June 28, 2010 Davis buys One and Three Burlington Woods
The Davis Cos., a Boston-based real estate investment, development, and management firm, has completed the acquisition of One and Three Burlington Woods, a two-building office park in Burlington. Eagle Pack debuts new dog food canned line
WellPet, a Tewksbury-based purveyor of natural pet foods, said its Eagle Pack brand is rolling out a new line of canned dog food. Mass. reaches $2.9m settlement with ExxonMobil
The Massachusetts attorney general says ExxonMobil Corp. and two affiliates have agreed to pay a $2.9 million civil penalty to resolve allegations that the company violated state air pollution laws. MassDevelopment issues bonds for Emerson
MassDevelopment said it has issued $134.5 million in tax-exempt and taxable bonds on behalf of Emerson College to help defray the college's costs for undertaking efforts that aim to "revitalize" Boston's Theater District and Downtown Crossing shopping area. Local gas prices drop 2 cents a gallon
The average price for gas in Massachusetts fell 2 cents to $2.709 a gallon in AAA?s latest weekly survey, AAA Southern New England said today. ADL taps Sheetz as New England chair
The Anti-Defamation League New England announced that Michael N. Sheetz has been unanimously elected as the new board chair for ADL?s New England Region. AS&E receives US government order
American Science and Engineering Inc. announced the receipt of a $6.7 million order for its X-ray detection technology that will be deployed by the US government for counterterrorism missions. Emerald BioStructures and FORMA enter partnership
Emerald BioStructures and FORMA Therapeutics, a Cambridge drug discovery company, announced the signing of a strategic partnership for the structure-based design of cancer drug candidates for FORMA's pipeline. Peabody bank teller sentenced in fraud case
A former bank teller from Peabody has been sentenced to nearly three and a half years in prison for stealing customer account information that led to the theft of more than $330,000. Tolerx starts new trial for diabetes treatment
Tolerx Inc., a Cambridge biopharmaceutical company that looks to develop drugs by modulating T cell activity, announced the start of a confirmatory Phase 3 clinical trial to further evaluate the drug candidate otelixizumab as a potential treatment for autoimmune new-onset type 1 diabetes. Today in Globe Business
A sample of Business stories from today's Boston Globe. | 
No comments:
Post a Comment